We’ve recently updated our valuation analysis.

Prothena Valuation

Is 0PT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0PT?

Other financial metrics that can be useful for relative valuation.

0PT key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue32.8x
Enterprise Value/EBITDA-13.5x
PEG Ration/a

Price to Sales Ratio vs Peers

How does 0PT's PS Ratio compare to its peers?

The above table shows the PS ratio for 0PT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average12x
BIO3 Biotest
2.5x9.5%€1.5b
FYB Formycon
31.3x47.0%€1.1b
MOR MorphoSys
1.8x15.2%€489.8m
HPHA Heidelberg Pharma
12.3x12.6%€213.8m
0PT Prothena
45.9x42.2%€2.5b


Price to Earnings Ratio vs Industry

How does 0PT's PE Ratio compare vs other companies in the European Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a32.1%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a32.1%
n/an/an/a
No more companies


Price to Sales Ratio vs Fair Ratio

What is 0PT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0PT PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio45.9x
Fair PS Ratio1.8x

Price-To-Sales vs Fair Ratio: 0PT is expensive based on its Price-To-Sales Ratio (45.9x) compared to the estimated Fair Price-To-Sales Ratio (1.8x).


Share Price vs Fair Value

What is the Fair Price of 0PT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0PT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€43.36
€79.48
+83.3%
21.6%€113.41€51.98n/a10
Mar ’24€52.72
€79.28
+50.4%
21.6%€113.12€51.85n/a10
Feb ’24€48.53
€77.86
+60.4%
21.0%€110.44€51.54n/a10
Jan ’24€55.22
€78.61
+42.4%
22.3%€113.05€51.82n/a9
Dec ’23€59.50
€78.12
+31.3%
23.5%€115.90€53.12n/a9
Nov ’23€64.54
€78.30
+21.3%
22.0%€111.53€52.72n/a9
Oct ’23€63.04
€75.28
+19.4%
20.6%€112.23€53.06n/a9
Sep ’23€27.18
€65.33
+140.4%
26.9%€98.43€44.29n/a8
Aug ’23€30.01
€62.62
+108.7%
26.3%€93.64€42.14n/a8
Jul ’23€25.46
€62.62
+146.0%
26.3%€93.64€42.14n/a8
Jun ’23€25.27
€62.62
+147.8%
26.3%€93.64€42.14n/a8
May ’23€28.07
€70.90
+152.6%
19.2%€93.99€44.18n/a7
Apr ’23€32.89
€68.56
+108.5%
17.9%€90.66€42.61n/a8
Mar ’23€30.60
€67.32
+120.0%
16.1%€88.29€45.91€52.728
Feb ’23€30.20
€72.61
+140.4%
17.8%€91.62€48.03€48.538
Jan ’23€40.40
€74.74
+85.0%
12.6%€91.24€66.44€55.228
Dec ’22€43.00
€74.74
+73.8%
12.6%€91.24€66.44€59.508
Nov ’22€47.20
€74.11
+57.0%
12.9%€88.76€64.63€64.547
Oct ’22€59.00
€69.57
+17.9%
18.6%€88.93€49.21€63.047
Sep ’22€56.50
€59.63
+5.5%
11.9%€69.86€48.56€27.187
Aug ’22€41.60
€58.61
+40.9%
10.6%€64.42€48.31€30.017
Jul ’22€43.40
€50.25
+15.8%
13.2%€62.81€41.04€25.468
Jun ’22€23.40
€27.30
+16.7%
29.7%€36.81€9.81€25.278
May ’22€22.40
€26.47
+18.2%
29.4%€36.55€10.20€28.077
Apr ’22€21.00
€26.47
+26.0%
29.4%€36.55€10.20€32.897
Mar ’22€18.30
€23.55
+28.7%
24.9%€28.99€9.94€30.607


Discover undervalued companies